Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Greinix, HT; Reiter, E; Keil, F; Fischer, G; Lechner, K; Dieckmann, K; Leitner, G; Schulenburg, A; Hoecker, P; Haas, OA; Knoebl, P; Mannhalter, C; Fonatsch, C; Hinterberger, W; Kalhs, P.
Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors.
Bone Marrow Transplant. 1998; 21(7):673-678
Doi: 10.1038/sj.bmt.1701152
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Between April 1982 and February 1997 39 patients (24 male, 15 female) with refractory acute leukemia and a median age of 31 years (19-51 years) received allogeneic marrow grafts from an HLA-identical sibling (n = 27), HLA-identical unrelated donor (MUD; n = 10) or 1-antigen mismatched unrelated donor (n = 2). Twenty-eight patients had acute myelogenous leukemia and 11 acute lymphoblastic leukemia. For conditioning most patients received total body irradiation combined with cyclophosphamide (n = 23) or etoposide (n = 7). For graft-versus-host disease prophylaxis patients received cyclosporin A (CsA) and methotrexate (MTX) (n = 20), MTX alone (n = 3), CsA and methylprednisone (n = 6), or CsA alone (n = 10), respectively. As of June 1997 probability of leukemia-free survival projected to 3 years after BMT was 14% for patients given sibling marrow grafts and 28% after MUD transplantation. Transplant-related mortality projected to 3 years was 32% after sibling and 37% after MUD marrow grafting. Although not significantly different, probability of relapse projected to 3 years after BMT was lower after MUD at 56% compared to 78% with sibling BMT. Thus, high-dose chemo/radiotherapy followed by allogeneic marrow infusion has a curative potential for patients with refractory leukemia and offers the chance of long-term disease-free survival for some patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Acute Disease -
- Adult -
- Bone Marrow Transplantation -
- Disease-Free Survival -
- Female -
- Histocompatibility Testing -
- Humans -
- Leukemia - mortality Leukemia - pathology Leukemia - therapy
- Male -
- Middle Aged -
- Recurrence -
- Tissue Donors -
- Transplantation, Homologous -
- Find related publications in this database (Keywords)
- poor risk acute leukemia
- sibling and unrelated marrow transplantation